A Closer Look: Hutchison MediTech TCM Deal With Nestle Reaches Into Pharma Development
This article was originally published in PharmAsia News
Executive Summary
A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&D firm’s long search for a partner.